Challenges in the Management of Severe Asthma: Role of Current and Future Therapies

Author(s): Ron Oliveinstein, Hamdan Al Jahdali, Nouf Alkhamis, Rabih Halwani, Saleh Al-Muhsen, Qutayba Hamid

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 7 , 2011

Become EABM
Become Reviewer
Call for Editor


Severe asthma is a complex and heterogeneous phenotype characterized by persistent symptoms and poor control. While some patients respond to high doses of inhaled corticosteroids in combination with long-acting beta-agonists, a significant subset require oral corticosteroids to achieve symptom control. This issue has led to the development of alternative therapeutic strategies for severe asthma. This article provides an overview of current therapeutic strategies and suggests how they can be best applied to the treatment of severe asthma. The article then reviews alternative therapeutic strategies including macrolide antibiotics, biologic agents, modulators of signal transduction pathways and bronchial thermoplasty. The challenge remains to determine the appropriate phenotype for each therapeutic strategy in view of the heterogeneity of severe asthma.

Keywords: Severe asthma, new asthma therapy, corticosteriods, macrolides, biologic agents, neutrophilic, beta2, obliterans, emphysema, pulmonary edema, eosinophilic pneumonia, ABPA, Churg-Strauss syndrome, benign, malignant tumors, co-morbidities, cigarette smoking, anti-inflammatory therapy, synergistically

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [703 - 711]
Pages: 9
DOI: 10.2174/138161211795428993
Price: $65

Article Metrics

PDF: 13